AdvanCell raised a $315 million Series D to advance its lead-based prostate cancer radiopharmaceutical program and to shore up U.S. manufacturing capacity for its radioactive therapy pipeline. The financing is positioned as a major step toward scaling production of a Pluvicto challenger, combining clinical execution with supply-chain readiness. For radiopharma, capacity expansion often determines whether trial and commercialization timelines can move in lockstep, especially for lead-based agents that require specialized handling and dedicated production workflows. The round also signals continued institutional appetite for radiopharmaceutical differentiation built on manufacturing leverage rather than purely early-stage science.